Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...

Neurosense Therapeutics (NASDAQ:NRSN) is developing novel treatments for neurodegenerative diseases like amyotrophic lateral ...

Founded in 2011 under the name M3 Biotechnology, Athira has been trying to develop small molecule drugs that help regenerate ...

Baldanza has largely kept a low profile aside from co-hosting a podcast on aviation since his sudden resignation in 2016. The ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

"According to the latest study from BCC Research, Antibody Drugs: Technologies and Global Markets is expected to grow from $242.6 billion in 2024 to $412.1 billion ...

I couldn’t have reached this point without the support and camaraderie of my training partners, who also ran the marathon ...